Insight into the epigenetic regulation of gene expression has deepened our understanding of development, homeostasis, and disease. Rapid progress has yielded new tools and methods to probe and monitor epigenetic modifications and transformed our understanding of the underlying molecular mechanisms. In 2016, we joined with ACS Medicinal Chemistry Letters, Biochemistry, and the Journal of Medicinal Chemistry to collaborate on special issues highlighting new and vital research in this dynamic area (https://pubs.acs.org/toc/acbcct/11/3). Given the surge in discoveries since then, ACS Chemical Biology is announcing a call for papers. This special issue is a joint initiative with ACS Chemical Neuroscience, ACS Infectious Diseases, ACS Pharmacology & Translational Science, Journal of Medicinal Chemistry, and Journal of Medicinal Chemistry Letters and a reflection of the breadth of ongoing epigenetic research. ACS Chemical Biology welcomes submissions that use chemical biology approaches or describe new chemical biology tools to understand or exploit epigenetic mechanisms or function; Articles, Reviews, and Letters are welcome. The scope of the special issue for our partner journals follows: ACS Chemical Neuroscience will focus on epigenetic mechanisms associated with neurogenesis, neural plasticity, as well as cognition and memory. Papers of interest also include those aimed at neuropsychiatric disorders for which epigenetic deregulation is a key driver of disease phenotype. ACS Infectious Diseases encourages manuscripts that investigate epigenetic processes that impact the survival, replication, or infection capacity of the pathogen, or the response from the host. ACS Pharmacology & Translational Science will focus on epigenetic biomarkers—both preclinical development and clinical application—in cancer and CNS disorders. The Journal of Medicinal Chemistry seeks submissions across the full spectrum of epigenetics, including epigenetic studies focused on human and nonhuman species. Finally, the ACS Medicinal Chemistry Letters special issue will be dedicated to advances in the understanding of chemical modulators of chromatin and RNA modifications. ACS Chemical Biology is a vibrant platform for the rapid communication of epigenetic research. Below we highlight several papers that describe advances in epigenetics research: Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites: https://pubs.acs.org/doi/10.1021/acschembio.0c00058 Engineered Reader Proteins for Enhanced Detection of Methylated Lysine on Histones: https://pubs.acs.org/doi/10.1021/acschembio.9b00651 The Activity of JmjC Histone Lysine Demethylase KDM4A is Highly Sensitive to Oxygen Concentrations: https://pubs.acs.org/doi/10.1021/acschembio.6b00958 Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action: https://pubs.acs.org/doi/10.1021/acschembio.7b00708 Selective Small-Molecule Targeting of a Triple Helix Encoded by the Long Noncoding RNA, MALAT1: https://pubs.acs.org/doi/10.1021/acschembio.8b00807 The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases: https://pubs.acs.org/doi/10.1021/acschembio.9b00289 Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach: https://pubs.acs.org/doi/10.1021/acschembio.8b00705 Methionine Adenosyltransferase Engineering to Enable Bioorthogonal Platforms for AdoMet-Utilizing Enzymes: https://pubs.acs.org/doi/10.1021/acschembio.9b00943 We are excited to be partnering with this group of ACS journals to publish a wide cross-section of the newest forefront developments in epigenetics research and look forward to receiving your exciting new research in the area! If you have any questions regarding this issue, these may be sent to [email protected]. Views expressed in this editorial are those of the author and not necessarily the views of the ACS. This article has not yet been cited by other publications.

中文翻译：

---

ACS表观遗传学化学生物学特刊–征文

对基因表达的表观遗传调控的深入了解加深了我们对发育，体内平衡和疾病的理解。快速的进步产生了探测和监测表观遗传修饰的新工具和方法，并转变了我们对基本分子机制的理解。2016年，我们与ACS药物化学快报，生物化学和药物化学杂志一起就特殊问题进行了合作，突出了这一动态领域的新的重要研究（https://pubs.acs.org/toc/acbcct/11/ 3）。鉴于此后的发现激增，ACS化学生物学家宣布征集论文。本期专刊是与ACS化学神经科学学院联合发起的，ACS传染病，ACS药理与转化科学，《药物化学杂志》和《药物化学杂志》，这反映了正在进行的表观遗传学研究的广度。ACS化学生物学欢迎使用化学生物学方法或描述新化学生物学工具来理解或利用表观遗传机制或功能的论文；欢迎文章，评论和来信。我们合作伙伴期刊的特刊范围如下：ACS化学神经科学将专注于与神经发生，神经可塑性以及认知和记忆有关的表观遗传机制。感兴趣的论文还包括针对神经精神疾病的论文，其表观遗传失调是疾病表型的关键驱动因素。ACS传染病鼓励使用手稿来研究表观遗传过程，这些过程会影响病原体的存活，复制或感染能力或宿主的反应。ACS药理与转化科学将专注于表观遗传生物标志物（包括临床前开发和临床应用），用于癌症和中枢神经系统疾病。在药物化学杂志寻求表观遗传学各个方面的研究成果，包括针对人类和非人类物种的表观遗传学研究。最后，《ACS药物化学快报》特刊将致力于增进对染色质和RNA修饰的化学调节剂的理解。ACS化学生物学是用于快速交流表观遗传研究的充满活力的平台。下面我们重点介绍描述表观遗传学研究进展的几篇论文：BRD4的共价片段筛选可鉴定与乙酰赖氨酸结合位点正交的可配体位点：https://pubs.acs.org/doi/10.1021/acschembio.0c00058工程读本用于在组蛋白上增强检测甲基化赖氨酸的蛋白质：https：//pubs.acs.org/doi/10.1021/acschembio.9b00651 JmjC组蛋白赖氨酸脱甲基酶KDM4A的活性对氧气浓度高度敏感：https：//pubs.acs。 org / doi / 10.1021 / acschembio.6b00958具有新型化学结构和异常作用方式的同工型选择性ATAD2化学探针：https：//pubs.acs.org/doi/10.1021/acschembio.7b00708选择性靶向三元组的小分子由长非编码RNA编码的螺旋MALAT1：https://pubs.acs.org/doi/10.1021/acschembio.8b00807临床上使用的铁螯合剂Deferasirox是表观遗传JumonjiC域组蛋白去甲基化酶的抑制剂：https://pubs.acs.org/doi/10.1021 /acschembio.9b00289通过PROTAC方法调节PCAF / GCN5免疫细胞功能：https://pubs.acs.org/doi/10.1021/acschembio.8b00705蛋氨酸腺苷基转移酶工程技术可为AdoMet利用酶的生物正交平台提供支持：https：// pubs.acs.org/doi/10.1021/acschembio.9b00943我们很高兴能与这组ACS期刊合作出版有关表观遗传学研究的最新前沿发展的广泛横断面，并期待着您在以下方面的激动人心的新研究该地区！如果您对此问题有任何疑问，可以将其发送给[电子邮件保护]。本社论中表达的观点只是作者的观点，不一定是ACS的观点。本文尚未被其他出版物引用。